Clinical Trial: A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274813) titled 'A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors' on Nov. 28.

Brief Summary: This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.

Study Start Date: Nov. 28

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Solid Tumors NSCLC

Intervention: DRUG: HLX37-Dose1

Patients with advanced/metastatic solid tumors

DRUG: HLX37-Dose2

5mg/kg Q3W

DRUG: HLX37-Dose3

10mg/kg Q3W

DRUG: HLX37-Dose4

20mg/kg Q3W

Recruitment Status: A...